Objective and Perceived Health Status of Elderly People With Moderate or Severe Haemophilia in France: an Ancillary Study of the FranceCoag Registry

NCT ID: NCT05218772

Last Updated: 2023-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

612 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-19

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Elderly people with serious haemophilia (PwSH), i.e., with moderate or severe haemophilia, have major comorbidities due to consequences of haemophilia. Also, the comorbidities related to age are added. Despite the existence of numerous studies on the objective health status of elderly PwSH, some limitations may be stated (need to update the results in a more contemporary context, no studies conducted in France, highlighted determinants focused on demographic and clinical factors).

On the contrary, the perceived health status of elderly PwSH has been little described. Only two studies specifically addressed the quality of life (QoL) of elderly PwSH. These studies reported an altered QoL in some domains, in comparison with reference values from the general population. However, some limitations may also be stated (need to bring results in a more contemporary context, no studies conducted in France, highlighted determinants focused on clinical factors).

Since serious haemophilia is a rare disease, studies are often performed on a small number of subjects. The present project relies on the FranceCoag registry, a unique exhaustive national cohort of PwSH followed over time among whom 612 are elderly PwSH.

Objectives:

Main objective: to describe the objective and perceived health status of elderly (≥60 y.o.) PwSH from of a French exhaustive national registry, and to compare their health status with that of the French general elderly population.

Secondary objective: to identify individual (demographic, clinical, social, psycho-cognitive) and collective characteristics (related to healthcare organisation), associated with the objective and perceived health status of elderly PwSH in France.

Materials and Methods:

A national, multicentric, observational, cross-sectional study will be conducted. It will be based on the participation of elderly PwSH already included in the FranceCoag registry. Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective). Therapeutic and clinical data related to haemophilia will be collected via the FranceCoag registry database. Data concerning healthcare organisation will be collected directly from investigators of Haemophilia Treatment Centres.

The main analysis will consist in the description and comparison of the health status with reference data from the French general elderly population. Standardisation methods will be used to take into account a potential imbalance between the study population and the reference population, related to age and especially to sex, as haemophilia is a predominantly male disease.

The secondary analysis will consist in the identification of potential determinants of the health status. Structural equation models will be performed to take into account the complexity of the relationships between the determinants.

Impact of the proposal Better understanding the impact of the disease on patients' experience is essential in a systematic global perspective of health, that aims to care and support the individual not only as a patient but also as a person in his/her environment. This study based on a registry will allow to improve the knowledge by updating literature data on the health status of elderly PwSH, adding elements to the rare literature data on the perceived health status, providing data in the French specific context, and identifying both classical and more original determinants of health status of elderly PwSH. These results will be used to better identify elderly PwSH at high risk of poor health status, to propose recommendations and to set up actions to offer them an adapted support, and to elaborate new versions of public health plans dedicated to haemophilia or to rare diseases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Moderate or Serious Haemophilia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Elderly people with moderate or severe haemophilia

Questionnaires

Intervention Type OTHER

Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaires

Each eligible participant will receive a questionnaire to complete concerning: objective health status; perceived health status (QoL assessed by the WHOQOL-Old questionnaire); demographic data; social data; psycho-cognitive data (anxious symptoms, depressive symptoms, use of coping strategies, time perspective)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* People with serious haemophilia, i.e., with (A or B) moderate or severe haemophilia;
* People aged 60 years or over;
* People included in the FranceCoag registry;
* People followed in one of the Haemophilia Treatment Centre participating in the study;
* People who do not oppose to participate in the study.

Exclusion Criteria

* People with comprehension disabilities;
* Participants who a posteriori oppose to participate in the study.
Minimum Eligible Age

60 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Amiens

Amiens, , France

Site Status RECRUITING

Ch Annecy - St Julien

Annecy, , France

Site Status RECRUITING

Chu de Besancon

Besançon, , France

Site Status RECRUITING

Chu de Bordeaux

Bordeaux, , France

Site Status RECRUITING

Chu Brest

Brest, , France

Site Status RECRUITING

Chu de Caen

Caen, , France

Site Status RECRUITING

Centre hospitalier Métropole Savoie

Chambéry, , France

Site Status RECRUITING

Chu Clermont-Ferrand

Clermont-Ferrand, , France

Site Status RECRUITING

Chu de Dijon

Dijon, , France

Site Status RECRUITING

Chu La Reunion

La Réunion, , France

Site Status RECRUITING

Chu Le Mans

Le Mans, , France

Site Status RECRUITING

Chru de Lille

Lille, , France

Site Status RECRUITING

Hospices Civils de Lyon

Lyon, , France

Site Status RECRUITING

Ap-Hm

Marseille, , France

Site Status RECRUITING

Chu Montpellier

Montpellier, , France

Site Status RECRUITING

Chu de Nancy

Nancy, , France

Site Status RECRUITING

Chu Nantes

Nantes, , France

Site Status RECRUITING

Chu de Nice

Nice, , France

Site Status RECRUITING

AP-HP

Paris, , France

Site Status RECRUITING

Chu Poitiers

Poitiers, , France

Site Status RECRUITING

Chu Reims

Reims, , France

Site Status RECRUITING

Chu de Rennes

Rennes, , France

Site Status RECRUITING

Chu de Rouen

Rouen, , France

Site Status RECRUITING

Chu St Etienne

Saint-Etienne, , France

Site Status RECRUITING

Chu Strasbourg

Strasbourg, , France

Site Status RECRUITING

Chu Toulouse

Toulouse, , France

Site Status RECRUITING

Chru de Tours

Tours, , France

Site Status RECRUITING

Ch Versailles

Versailles, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Noémie Resseguier, MD

Role: CONTACT

04.91.32.42.72

Fatimata-Zahra DIAGNE

Role: CONTACT

04 91 38 20 62

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Annelise VOYER

Role: primary

Claire REYNES

Role: primary

Alexandra FOURNEL

Role: primary

Sabine-Marie CASTET

Role: primary

Brigitte PAN-PETESCH

Role: primary

Yohann REPESSE

Role: primary

Valerie GAY

Role: primary

Aurelien LEBRETON

Role: primary

Fabienne GENRE VOLOT

Role: primary

Stephane VANDERBECKEN

Role: primary

Vincent CUSSAC

Role: primary

Antoine RAUCH

Role: primary

Anne LIENHART

Role: primary

Noemie Resseguier

Role: primary

Christine BIRON-ANDREANI

Role: primary

Birgit FROTSCHER

Role: primary

Marc TROSSAËRT

Role: primary

Pierre-Simon ROHRLICH

Role: primary

na na

Role: primary

Mathieu PUYADE

Role: primary

Philippe NGUYEN

Role: primary

Benoît GUILLET

Role: primary

Pierre CHAMOUNI

Role: primary

Brigitte TARDY

Role: primary

Dominique DESPREZ

Role: primary

Marie-Lea PIEL-JULIAN

Role: primary

Laurent ARDILLON

Role: primary

Emmanuelle DE RAUCOURT

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.